Novartis' Entresto Blockbuster Status On Track After CHMP Backing
This article was originally published in Scrip
Executive Summary
Novartis' heart failure pill Entresto is already predicted to reach blockbuster status on the strength of its July approval in the US and now formal recommendation by CHMP in Europe for patients with reduced ejection fraction – representing some 50% of chronic heart failure patients - but those prospects could soar if an ongoing Phase III study presents the opportunity to eventually move the agent into the other half of chronic heart failure patients, those having preserved ejection fraction.